0000000001189138

AUTHOR

Lifermann F

showing 2 related works from this author

Demographic and clinical data in acquired hemophilia A

2012

Summary.  Background:  Acquired hemophilia A (AHA) is a rare autoimmune disease caused by autoantibodies against coagulation factor VIII and characterized by spontaneous hemorrhage in patients with no previous family or personal history of bleeding. Although data on several AHA cohorts have been collected, limited information is available on the optimal management of AHA. Objectives:  The European Acquired Hemophilia Registry (EACH2) was established to generate a prospective, large-scale, pan-European database on demographics, diagnosis, underlying disorders, bleeding characteristics, treatment and outcome of AHA patients. Results:  Five hundred and one (266 male, 235 female) patients from …

RegistrieMalePediatricsdiagnosismedicine.medical_treatmentHemostatic TechniqueKaplan-Meier EstimateregistryTHERAPYSettore MED/15 - Malattie Del SangueImmunosuppressive AgentIMMUNOADSORPTIONRisk FactorsPregnancy80 and overProspective StudiesRegistriesProspective cohort studyhealth care economics and organizationsAged 80 and overtreatmentImmunosuppressionHematologyMiddle AgedFACTOR-VIII INHIBITORAcquired hemophilia; Demographics; Diagnosis; Outcome; Registry; Treatment; Aged; Aged 80 and over; Autoantibodies; Chi-Square Distribution; Europe; Factor VIII; Female; Hemostatic Techniques; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Middle Aged; Pregnancy; Prospective Studies; Registries; Risk Assessment; Risk Factors; Treatment Outcome; Hemophilia A; HemorrhageAutoantibodieEuropeTreatment Outcomeacquired hemophilia; demographics; diagnosis; outcome; registry; treatmentoutcomeINTRAVENOUS GAMMA-GLOBULINFemaleacquired hemophiliaImmunosuppressive AgentsHumanmedicine.medical_specialtyHemorrhageHemophilia AMalignancyRisk Assessmenthemophilia registrydemographicsmedicineHumansMETAANALYSISAutoantibodiesAgedAutoimmune diseasePregnancyChi-Square DistributionFactor VIIIHemostatic Techniquesbusiness.industryRisk FactorAutoantibodymedicine.diseaseSurgeryProspective StudieHemostasisbusinessChi-squared distributionJournal of Thrombosis and Haemostasis
researchProduct

Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis: Data From a European Collaborative Study.

2021

OBJECTIVE To describe the efficacy and safety of biologics for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA). METHODS A retrospective European collaborative study was conducted in patients with EGPA who received treatment with biologics for refractory and/or relapsing disease. RESULTS Among the 147 patients with EGPA included in the study, 63 received rituximab (RTX), 51 received mepolizumab (MEPO), and 33 received omalizumab (OMA). At the time of inclusion, the median Birmingham Vasculitis Activity Score (BVAS) was 8.5 (interquartile range [IQR] 5-13) in the RTX group, while the median BVAS in the OMA group was 2 (IQR 1-4.5) and the median BVAS in the MEPO group was…

AdultMalemedicine.medical_specialtyImmunologyBirmingham Vasculitis Activity ScoreOmalizumabOmalizumabChurg-Strauss SyndromeAntibodies Monoclonal Humanized03 medical and health sciences0302 clinical medicineRheumatologyInterquartile rangeRecurrenceInternal medicinemedicineImmunology and AllergyHumansImmunologic Factors030212 general & internal medicineTreatment FailureAdverse effectGlucocorticoidsAgedRetrospective Studies030203 arthritis & rheumatologyBiological Productsbusiness.industryMiddle Agedmedicine.diseaseAsthmaTreatment OutcomeRituximabFemaleVasculitisbusinessGranulomatosis with polyangiitisRituximabMepolizumabmedicine.drugArthritisrheumatology (Hoboken, N.J.)References
researchProduct